Back to top

Image: Bigstock

Alnylam Pharmaceuticals, Inc.

Read MoreHide Full Article

Alnylam expects 2017 to be a pivotal year with its first phase III data read out from the APOLLO study for its late-stage pipeline candidate patisiran. It also plans to advance three additional programs into late-stage trials in 2017. The company expects to achieve the profile of three marketed products by the end of 2020. Shares of the company have outperformed the Medical-Biomedical/Genetics industry year-to-date. The company’s RNAi technology has allowed it to ink collaborations with leading pharmaceutical and life sciences companies like Novartis, Roche, Monsanto and Sanofi. These deals not only provide it with funds but also take its RNAi technology outside the core focus area. However, the company’s dependence on collaborations for revenues is concerning.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alnylam Pharmaceuticals, Inc. (ALNY) - free report >>

Published in